Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CT-179 + dordaviprone
- Development stage
- Preclinical
- Lead developer
- Curtana Pharmaceuticals
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
CT-179 + Modeyso (dordaviprone) is an investigational combination therapy combining CT-179, a brain-penetrant small molecule inhibitor of oligodendrocyte transcription factor 2 (OLIG2), with Modeyso (dordaviprone), an FDA-approved small molecule that acts as a mitochondrial caseinolytic protease P (ClpP) agonist and dopamine receptor D2 (DRD2) antagonist. Developed preclinically for the treatment of diffuse midline glioma (DMG), including H3 K27M-mutant diffuse midline glioma, this combination aims to synergistically target brain tumor stem cells, disrupt mitochondrial metabolism, and overcome resistance to monotherapy. Preclinical studies presented at the 2026 Society for Neuro-Oncology (SNO) Annual Meeting demonstrated that combining CT-179 with dordaviprone leads to enhanced anti-tumor efficacy and apoptosis in patient-derived models of diffuse midline glioma.
- Other names
- CT-179 + ModeysoModeyso + CT-179dordaviprone + CT-179
02
Targets
AKT (RAC-alpha serine/threonine-protein kinase)ATF4 (Activating transcription factor 4)CLPP (Caseinolytic mitochondrial matrix peptidase proteolytic subunit)ClpX (Caseinolytic mitochondrial matrix peptidase chaperone subunit X)DRD3 (Dopamine receptor D3)ERKOLIG2 (Oligodendrocyte transcription factor 2)DRD2 (Dopamine D2 Receptor)
Beyond the preview
Go deeper on CT-179 + dordaviprone.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CT-179 + dordaviprone.